Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 16/20 | 0.51 |
| ▸ | CA2 | P00918 | 15/20 | 0.51 |
| ▸ | CA1 | P00915 | 14/20 | 0.51 |
| ▸ | CA12 | O43570 | 13/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 8/20 | 0.51 |
| ▸ | CA5A | P35218 | 3/20 | 0.47 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.47 |
| ▸ | CA3 | P07451 | 2/20 | 0.47 |
| ▸ | CA6 | P23280 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | IKBKB | O14920 | 2/20 | 0.44 |
| ▸ | CHUK | O15111 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4135236 | 0.82 | IKBKB (0.51) | CA9CA2CA1CA12IKBKB | |
| SCHEMBL27547124 | 0.80 | KDM4E (0.43) | CA9CA12CYP2C19PTGS2 | |
| SCHEMBL842987 | 0.78 | FOLH1 (0.49) | — | |
| SCHEMBL6974190 | 0.78 | ALDH1A1 (0.49) | — | |
| SCHEMBL6978903 | 0.76 | CA2 (0.65) | CA9CA2CA1CA12CA14 | |
| SCHEMBL843489 | 0.75 | CYP1A2 (0.48) | — | |
| SCHEMBL4638012 | 0.74 | TSHR (0.36) | — | |
| P-Toluenesulfonamide SCHEMBL28172170 | 0.74 | CA1 (0.60) | CA9CA2CA1CA12CA14 | |
| SCHEMBL28092791 | 0.74 | PTGS2 (0.47) | PTGS2 | |
| SCHEMBL28503156 | 0.72 | EGFR (0.52) | CA9CA2CA1CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023741-A1 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AG (DE) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023741-A1 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | PTGER2, PTGER1, PTGDR2 | CA9 4855/4885CA2 4597/4885CA1 4884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.